ATE409485T1 - Pharmazeutische zusammensetzungen inhibitoren von fab i und weitere antibiotika enthaltend - Google Patents

Pharmazeutische zusammensetzungen inhibitoren von fab i und weitere antibiotika enthaltend

Info

Publication number
ATE409485T1
ATE409485T1 AT04721257T AT04721257T ATE409485T1 AT E409485 T1 ATE409485 T1 AT E409485T1 AT 04721257 T AT04721257 T AT 04721257T AT 04721257 T AT04721257 T AT 04721257T AT E409485 T1 ATE409485 T1 AT E409485T1
Authority
AT
Austria
Prior art keywords
antibiotics
inhibitors
pharmaceutical compositions
compositions containing
containing fab
Prior art date
Application number
AT04721257T
Other languages
English (en)
Inventor
Judd Berman
Molly Schmid
John Mendlein
Nachum Kaplan
Original Assignee
Affinium Pharm Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Affinium Pharm Inc filed Critical Affinium Pharm Inc
Application granted granted Critical
Publication of ATE409485T1 publication Critical patent/ATE409485T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4422—1,4-Dihydropyridines, e.g. nifedipine, nicardipine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/554—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one sulfur as ring hetero atoms, e.g. clothiapine, diltiazem
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
AT04721257T 2003-03-17 2004-03-17 Pharmazeutische zusammensetzungen inhibitoren von fab i und weitere antibiotika enthaltend ATE409485T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US45518903P 2003-03-17 2003-03-17
US47697003P 2003-06-09 2003-06-09
US48837903P 2003-07-18 2003-07-18

Publications (1)

Publication Number Publication Date
ATE409485T1 true ATE409485T1 (de) 2008-10-15

Family

ID=33033147

Family Applications (1)

Application Number Title Priority Date Filing Date
AT04721257T ATE409485T1 (de) 2003-03-17 2004-03-17 Pharmazeutische zusammensetzungen inhibitoren von fab i und weitere antibiotika enthaltend

Country Status (7)

Country Link
US (2) US7879872B2 (de)
EP (1) EP1608377B1 (de)
JP (1) JP4880448B2 (de)
AT (1) ATE409485T1 (de)
CA (1) CA2519429C (de)
DE (1) DE602004016831D1 (de)
WO (1) WO2004082586A2 (de)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BRPI0014470B1 (pt) * 1999-10-08 2016-08-23 Affinium Pharm Inc compostos inibidores de fab i, composição farmacêutica, processo de preparação dos compostos e uso dos compostos para a produção de medicamento para tratamento de infecções bacterianas
WO2003088897A2 (en) * 2001-04-06 2003-10-30 Affinium Pharmaceuticals, Inc. Fab i inhibitors
US7790709B2 (en) * 2002-12-06 2010-09-07 Affinium Pharmaceuticals, Inc. Heterocyclic compounds, methods of making them and their use in therapy
ATE409485T1 (de) 2003-03-17 2008-10-15 Affinium Pharm Inc Pharmazeutische zusammensetzungen inhibitoren von fab i und weitere antibiotika enthaltend
EP2848614A3 (de) * 2004-06-04 2015-07-29 Debiopharm International SA Acrylamidderivate und ihre Verwendung als Antibiotika
EP2502925A1 (de) * 2004-10-27 2012-09-26 Janssen Pharmaceutica NV Pyridinimidazole und Aza-indole als Progesteronrezeptor-Modulatoren
WO2007067416A2 (en) * 2005-12-05 2007-06-14 Affinium Pharmaceuticals, Inc. Heterocyclylacrylamide compounds as fabi inhibitors and antibacterial agents
WO2007086584A1 (ja) * 2006-01-30 2007-08-02 Meiji Seika Kaisha, Ltd. 新規ＦａｂＫおよびＦａｂＩ／Ｋ阻害剤
CA2658506C (en) * 2006-07-20 2016-01-26 Affinium Pharmaceuticals, Inc. Acrylamide derivatives as fab 1 inhibitors
FR2912133B1 (fr) 2007-02-01 2009-04-24 Univ Grenoble 1 Nouveaux derives indoliques,leurs procedes de preparation et leurs utilisations notamment en tant qu'antibacteriens
US8263613B2 (en) * 2007-02-16 2012-09-11 Affinium Pharmaceuticals, Inc. Salts, prodrugs and polymorphs of fab I inhibitors
CA2682190C (en) * 2007-03-29 2015-01-27 Medtronic, Inc. Biodegradable, polymer coverings for breast implants
FR2928070A1 (fr) * 2008-02-27 2009-09-04 Sumitomo Chemical Co Composition agricole, utilisation d'un compose pour sa production et procede pour matriser ou prevenir les maladies des plantes.
SG177628A1 (en) * 2009-07-30 2012-03-29 Univ Singapore Small molecule inhibitors of isoprenylcysteine carboxyl methyltransferase with potential anticancer activity
EP3470407B1 (de) 2010-11-05 2024-01-24 Firmenich Incorporated Als modulatoren von trpm8 nützliche verbindungen
WO2013042035A1 (en) * 2011-09-19 2013-03-28 Vitas Pharma Research Private Limited Heterocyclic compounds as inhibitors of fatty acid biosynthesis for bacterial infections
CN102408346B (zh) * 2011-10-31 2014-07-02 江苏阿尔法药业有限公司 一种4,5-二甲氧基-1-（甲基氨基甲基）-苯并环丁烷的制备方法
SG11201408100YA (en) 2012-06-19 2015-01-29 Debiopharm Int Sa Prodrug derivatives of (e)-n-methyl-n-((3-methylbenzofuran-2-yl)methyl)-3-(7-oxo-5,6,7,8-tetrahydro-1,8-naphthyridin-3-yl)acrylamide
WO2014072930A2 (en) * 2012-11-09 2014-05-15 Aurigene Discovery Technologies Limited Fused pyridine derivatives as antibacterial agents
US20150065416A1 (en) * 2013-08-29 2015-03-05 Fab Pharma Sas Novel drug combination
US10392371B2 (en) 2015-10-01 2019-08-27 Senomyx, Inc. Compounds useful as modulators of TRPM8
LT3419628T (lt) 2016-02-26 2021-01-25 Debiopharm International Sa Medikamentas diabetinėms pėdų infekcijoms gydyti
MX2020006587A (es) 2017-12-22 2020-12-10 Ravenna Pharmaceuticals Inc Derivados de aminopiridina como inhibidores de fosfatidilinositol fosfato cinasa.
US11691967B2 (en) 2018-03-12 2023-07-04 The Board Of Trustees Of The University Of Illinois Antibiotics effective for gram-negative pathogens
KR20200009744A (ko) * 2018-07-20 2020-01-30 크리스탈지노믹스(주) Fab I 저해제를 포함하는 경구투여용 약제학적 조성물 및 그 제조방법
DK3880675T3 (da) * 2018-11-12 2024-12-02 Debiopharm Int Sa Antibiotiske forbindelser, fremgangsmåder til fremstilling deraf, farmaceutiske sammensætninger indeholdende disse og anvendelser deraf
LT3923914T (lt) 2019-02-14 2023-07-25 Debiopharm International S.A. Afabicino kompozicija, jos gamybos būdas
PH12021553086A1 (en) 2019-06-14 2023-08-14 Debiopharm Int Sa Medicament and use thereof for treating bacterial infections involving biofilm
TW202112767A (zh) 2019-06-17 2021-04-01 美商佩特拉製藥公司 作為磷脂酸肌醇磷酸激酶抑制劑之胺基吡啶衍生物
CN110763798B (zh) * 2019-11-16 2022-02-15 江西国药有限责任公司 一种盐酸土霉素含量的检测方法
WO2024175768A1 (en) * 2023-02-24 2024-08-29 Debiopharm International S.A. Combination of fabi inhibitor and antibiotic agent

Family Cites Families (110)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3828068A (en) 1971-05-10 1974-08-06 Tenneco Chem ((substituted indazolyl)-n1-methyl)carbamates
US4154943A (en) 1977-12-29 1979-05-15 University Of Vermont Preparation of vincadifformine
FR2619111B1 (fr) 1987-08-07 1991-01-11 Synthelabo Derives de (piperidinyl-4)methyl-2 tetrahydro-1,2,3,4 9h-pyrido (3,4-b) indole, leur preparation et leur application en therapeutique
CA2020437A1 (en) 1989-07-05 1991-01-06 Yoshihide Fuse Cinnamamide derivative
HU210679B (en) 1991-11-21 1995-06-28 Richter Gedeon Vegyeszet Process for producing new tetrahydro-pyrido/3,4-b/indol derivatives and pharmaceutical compositions containing the same
FR2692575B1 (fr) 1992-06-23 1995-06-30 Sanofi Elf Nouveaux derives du pyrazole, procede pour leur preparation et compositions pharmaceutiques les contenant.
US5614551A (en) 1994-01-24 1997-03-25 The Johns Hopkins University Inhibitors of fatty acid synthesis as antimicrobial agents
US6176842B1 (en) * 1995-03-08 2001-01-23 Ekos Corporation Ultrasound assembly for use with light activated drugs
US5989832A (en) * 1995-04-21 1999-11-23 Microcide Pharmaceuticals, Inc. Method for screening for non-tetracycline efflux pump inhibitors
ZA963758B (en) * 1995-05-11 1997-11-10 Sandoz Ag Antibacterial compounds.
US6057291A (en) * 1995-06-02 2000-05-02 University Of British Columbia Antimicrobial cationic peptides
NZ512609A (en) * 1996-02-29 2003-03-28 Fujisawa Pharmaceutical Co Synthetic sweeteners, their production and uses thereof
US6239154B1 (en) * 1996-03-08 2001-05-29 Adolor Corporation Kappa agonist compounds pharmaceutical formulations and method of prevention and treatment of pruritus therewith
US6367985B1 (en) 1996-03-12 2002-04-09 Intellectual Property Company Optical connector using large diameter alignment features
US6451816B1 (en) 1997-06-20 2002-09-17 Klinge Pharma Gmbh Use of pyridyl alkane, pyridyl alkene and/or pyridyl alkine acid amides in the treatment of tumors or for immunosuppression
US6503881B2 (en) * 1996-08-21 2003-01-07 Micrologix Biotech Inc. Compositions and methods for treating infections using cationic peptides alone or in combination with antibiotics
US6995254B1 (en) * 1996-08-28 2006-02-07 Affinium Pharmaceuticals, Inc. Polynucleotide encoding the enoyl-acyl carrier protein reductase of Staphylococcus aureus, FAB I
SK284973B6 (sk) * 1996-09-20 2006-03-02 Meiji Seika Kaisha Ltd. Kryštalická forma Cefditoren pivoxylu a spôsob jej výroby
US6521408B1 (en) * 1997-09-25 2003-02-18 National Institute Of Agrobiological Sciences Method for assessing a function of a gene
DE19641437A1 (de) * 1996-10-08 1998-04-09 Basf Ag 1,3-Bis-(N-lactamyl)propane und deren pharmazeutische und kosmetische Verwendung
DE19652239A1 (de) 1996-12-16 1998-06-18 Bayer Ag Verwendung von 7-(2-Oxa-5,8-diazabicyclo[4.3.0]non-8-yl)-chinolon- und -naphthyridoncarbonsäure-Derivaten zur Therapie von Helicobacter-pylori-Infektionen und den damit assoziierten gastroduodenalen Erkrankungen
SI9600371B (sl) * 1996-12-18 2005-04-30 LEK, tovarna farmacevtskih in kemi�nih izdelkov, d.d. Etilidenski derivati tricikličnih karbapenemov
EP0973767A1 (de) 1997-03-31 2000-01-26 Dupont Pharmaceuticals Company Indazol zyklische harnstoffderivate als hiv protease-hemmer
ES2303351T3 (es) 1997-04-01 2008-08-01 Thomas Julius Borody Metodos y composiciones para tratar enfermedades intestinales inflamatorias.
US6406880B1 (en) 1997-05-02 2002-06-18 Integrated Research Technology, Llc Betaines as adjuvants to susceptibility testing and antimicrobial therapy
US6184363B1 (en) 1997-06-13 2001-02-06 Northwestern University Inhibitors of β-lactamases and uses therefor
KR20010014105A (ko) 1997-06-23 2001-02-26 가마쿠라 아키오 헬리코박터 감염에 기인한 질환의 예방 또는 치료제
AUPO758297A0 (en) 1997-06-27 1997-07-24 Rowe, James Baber Control of acidic gut syndrome
US6198000B1 (en) 1997-07-07 2001-03-06 Pfizer Inc. Intermediates useful in the synthesis of quinoline antibiotics
HN1998000106A (es) 1997-08-01 1999-01-08 Pfizer Prod Inc Composiciones parenterales de alatroflaxacino
US5932743A (en) 1997-08-21 1999-08-03 American Home Products Corporation Methods for the solid phase synthesis of substituted indole compounds
GB9717804D0 (en) 1997-08-22 1997-10-29 Zeneca Ltd Chemical compounds
US6432444B1 (en) 1997-10-31 2002-08-13 New Horizons Diagnostics Corp Use of bacterial phage associated lysing enzymes for treating dermatological infections
EP0950109A1 (de) * 1997-10-31 1999-10-20 Novartis AG Glyphosat resistente transgene pflanzen
SE9704404D0 (sv) * 1997-11-28 1997-11-28 Astra Ab New compounds
GB9725244D0 (en) * 1997-11-29 1998-01-28 Zeneca Ltd Chemical compounds
DE19753298A1 (de) * 1997-12-01 1999-06-02 Basf Ag Verfahren zur Herstellung von festen Dosierungsformen
AU736555B2 (en) * 1998-01-07 2001-08-02 Meiji Seika Pharma Co., Ltd. A composition comprising a crystallographically stable, amphorous cephalosporin and processes for the preparation thereof
US6184380B1 (en) 1999-01-25 2001-02-06 Pfizer Inc. Process for preparing naphthyridones and intermediates
US6248343B1 (en) * 1998-01-20 2001-06-19 Ethicon, Inc. Therapeutic antimicrobial compositions
PA8466701A1 (es) 1998-01-21 2000-09-29 Pfizer Prod Inc Comprimido de mesilato de trovafloxacino
US6204279B1 (en) * 1998-06-03 2001-03-20 Microcide Pharmaceuticals, Inc. Peptidomimetic efflux pump inhibitors
RU2241489C2 (ru) * 1998-02-27 2004-12-10 Биора Биоэкс Аб Композиции матриксных протеинов для залечивания ран
US6350738B1 (en) * 1998-03-06 2002-02-26 Brigham Young University Steroid derived antibiotics
DE19820801A1 (de) 1998-05-09 1999-11-25 Gruenenthal Gmbh Orale Arzneiformen mit reproduzierbarer Wirkstofffreisetzung von Gatifloxacin oder pharmazeutisch verwendbaren Salzen oder Hydraten
DE19821039A1 (de) 1998-05-11 1999-11-18 Bayer Ag Verfahren zur Herstellung von (S,S)-Benzyl-2,8-diazabicyclo[4.3.0]nonan
US6399629B1 (en) * 1998-06-01 2002-06-04 Microcide Pharmaceuticals, Inc. Efflux pump inhibitors
US6428579B1 (en) 1998-07-01 2002-08-06 Brown University Research Foundation Implantable prosthetic devices coated with bioactive molecules
US6423741B1 (en) 1998-07-10 2002-07-23 Council Of Scientific And Industrial Research Anti-microbial composition and method for producing the same
GB9815567D0 (en) 1998-07-18 1998-09-16 Glaxo Group Ltd Antiviral compound
US6514962B1 (en) * 1998-08-04 2003-02-04 Takeda Schering-Plough Animal Health K.K. Stabilized preparations of β-lactam antibiotic
JP5138128B2 (ja) 1998-08-21 2013-02-06 千寿製薬株式会社 水性液剤
US6461607B1 (en) * 1998-08-24 2002-10-08 Ganeden Biotech, Inc. Probiotic, lactic acid-producing bacteria and uses thereof
US6518487B1 (en) * 1998-09-23 2003-02-11 Pioneer Hi-Bred International, Inc. Cyclin D polynucleotides, polypeptides and uses thereof
US6509327B1 (en) 1998-09-30 2003-01-21 Alcon Manufacturing, Ltd. Compositions and methods for treating otic, ophthalmic and nasal infections
US6395746B1 (en) 1998-09-30 2002-05-28 Alcon Manufacturing, Ltd. Methods of treating ophthalmic, otic and nasal infections and attendant inflammation
TW526202B (en) * 1998-11-27 2003-04-01 Shionogi & Amp Co Broad spectrum cephem having benzo[4,5-b]pyridium methyl group of antibiotic activity
US6515113B2 (en) 1999-02-18 2003-02-04 The Regents Of The University Of California Phthalamide lanthanide complexes for use as luminescent markers
US6248363B1 (en) 1999-11-23 2001-06-19 Lipocine, Inc. Solid carriers for improved delivery of active ingredients in pharmaceutical compositions
US6294192B1 (en) 1999-02-26 2001-09-25 Lipocine, Inc. Triglyceride-free compositions and methods for improved delivery of hydrophobic therapeutic agents
US6267985B1 (en) 1999-06-30 2001-07-31 Lipocine Inc. Clear oil-containing pharmaceutical compositions
WO2000052035A1 (en) * 1999-03-03 2000-09-08 Princeton University Bacterial transglycosylases: assays for monitoring the activity using lipid ii substrate analogs and methods for discovering new antibiotics
US6495161B1 (en) * 1999-03-09 2002-12-17 Vivorx, Inc. Cytoprotective biocompatible containment systems for biologically active materials and methods of making same
US6239113B1 (en) 1999-03-31 2001-05-29 Insite Vision, Incorporated Topical treatment or prevention of ocular infections
US6224579B1 (en) * 1999-03-31 2001-05-01 The Trustees Of Columbia University In The City Of New York Triclosan and silver compound containing medical devices
WO2000059941A1 (en) * 1999-04-08 2000-10-12 The General Hospital Corporation Purposeful movement of human migratory cells away from an agent source
CO5180550A1 (es) 1999-04-19 2002-07-30 Smithkline Beecham Corp Inhibidores de fab i
US6290946B1 (en) * 1999-05-13 2001-09-18 Geltex Pharmaceuticals, Inc. Anionic polymers as toxin binders and antibacterial agents
US6514535B2 (en) * 1999-05-21 2003-02-04 Noveon Ip Holdings Corp. Bioadhesive hydrogels with functionalized degradable crosslinks
AR024077A1 (es) 1999-05-25 2002-09-04 Smithkline Beecham Corp Compuestos antibacterianos
AR024158A1 (es) * 1999-06-01 2002-09-04 Smithkline Beecham Corp Compuestos antibacterianos
US6239141B1 (en) 1999-06-04 2001-05-29 Pfizer Inc. Trovafloxacin oral suspensions
CO5180605A1 (es) 1999-06-23 2002-07-30 Smithkline Beecham Corp Compuestos de indol
CA2282066C (en) 1999-06-29 2010-09-07 Smithkline Beecham Corporation Methods of use of quinolone compounds against atypical upper respiratory pathogenic bacteria
US6309663B1 (en) 1999-08-17 2001-10-30 Lipocine Inc. Triglyceride-free compositions and methods for enhanced absorption of hydrophilic therapeutic agents
US6500459B1 (en) * 1999-07-21 2002-12-31 Harinderpal Chhabra Controlled onset and sustained release dosage forms and the preparation thereof
US6346391B1 (en) 1999-07-22 2002-02-12 Trustees Of Tufts College Methods of reducing microbial resistance to drugs
WO2001013956A2 (en) * 1999-08-26 2001-03-01 Ganeden Biotech, Inc. Use of emu oil a carrier for antifungal, antibacterial, and antiviral medications
US6221859B1 (en) 1999-08-27 2001-04-24 Merck & Co., Inc. Carbapenem antibacterial compositions and methods of the treatment
US6174878B1 (en) 1999-08-31 2001-01-16 Alcon Laboratories, Inc. Topical use of kappa opioid agonists to treat otic pain
CN1373674A (zh) 1999-09-11 2002-10-09 宝洁公司 易流动液体载体
DK1142573T3 (da) 1999-09-17 2006-04-10 Daiichi Asubio Pharma Co Ltd Farmaceutiske præparater omfattende faropenem-natrium og en diaminacetatforbindelse til forbedring af absorption i mave-tarm-kanalen
US6500463B1 (en) 1999-10-01 2002-12-31 General Mills, Inc. Encapsulation of sensitive components into a matrix to obtain discrete shelf-stable particles
WO2001026654A1 (en) * 1999-10-08 2001-04-19 Smithkline Beecham Corporation Fab i inhibitors
JP4831907B2 (ja) * 1999-10-08 2011-12-07 アフィニアム・ファーマシューティカルズ・インコーポレイテッド ＦａｂＩ阻害剤
BRPI0014470B1 (pt) * 1999-10-08 2016-08-23 Affinium Pharm Inc compostos inibidores de fab i, composição farmacêutica, processo de preparação dos compostos e uso dos compostos para a produção de medicamento para tratamento de infecções bacterianas
US6730684B1 (en) * 1999-10-08 2004-05-04 Affinium Pharmaceuticals, Inc. Fab I inhibitors
US6762201B1 (en) * 1999-10-08 2004-07-13 Affinium Pharmaceuticals, Inc. Fab I inhibitors
CA2323008C (en) 1999-10-11 2005-07-12 Pfizer Inc. Pharmaceutically active compounds
ES2225237T3 (es) 1999-10-19 2005-03-16 Sato Pharmaceutical Co. Ltd. Agentes antimicrobianos de tipo 4-oxoquinolizina que tienen cadenas principales de 2-piridona como estructura parcial.
US6951729B1 (en) * 1999-10-27 2005-10-04 Affinium Pharmaceuticals, Inc. High throughput screening method for biological agents affecting fatty acid biosynthesis
CN1188111C (zh) 1999-10-29 2005-02-09 耐科塔医药公司 分散性得到改进的干粉组合物
US6531291B1 (en) 1999-11-10 2003-03-11 The Trustees Of Columbia University In The City Of New York Antimicrobial activity of gemfibrozil and related compounds and derivatives and metabolites thereof
US6514986B2 (en) 2000-11-22 2003-02-04 Wockhardt Limited Chiral fluoroquinolone arginine salt forms
KR100327596B1 (ko) * 1999-12-31 2002-03-15 박종섭 Ｓｅｇ 공정을 이용한 반도체소자의 콘택 플러그 제조방법
US6372752B1 (en) 2000-02-07 2002-04-16 Genzyme Corporation Inha inhibitors and methods of use thereof
ES2179729B1 (es) * 2000-03-23 2003-12-16 Dreiman Lab Farmaceuticos S A Forma farmaceutica solida de administracion oral dispersable en agua, que comprende rifampicina, isoniazida y piridoxina hidrocloruro, procedimiento para su obtencion y forma de presentacion de dicha forma farmaceutica.
AU2000255628A1 (en) 2000-03-28 2001-10-08 Council Of Scientific And Industrial Research Formulation comprising thymol useful in the treatment of drug resistant bacterial infections
JP2003531184A (ja) 2000-04-21 2003-10-21 ローディア／カイレックス・インコーポレイテッド （ｒ）−１−（アリールオキシ）プロパン−２−オールの製造方法
WO2002007682A1 (en) * 2000-07-26 2002-01-31 Vyden John K Methods for treating atopic disorders
US6288239B1 (en) * 2000-09-19 2001-09-11 Board Of Trustees Operating Michigan State University 5-trityloxymethyl-oxazolidinones and process for the preparation thereof
US7048926B2 (en) 2000-10-06 2006-05-23 Affinium Pharmaceuticals, Inc. Methods of agonizing and antagonizing FabK
AU2000277557A1 (en) * 2000-10-06 2002-04-22 Smith Kline Beecham Corporation Methods of agonizing and antagonizing fabk
US6821746B2 (en) * 2000-10-06 2004-11-23 Affinium Pharmaceuticals, Inc. Methods of screening for FabK antagonists and agonists
US6388070B1 (en) * 2001-01-05 2002-05-14 Orchid Chemicals & Pharmaceuticals Ltd. Thioester derivatives of thiazolyl acetic acid and their use in the preparation of cephalosporin compounds
US6495158B1 (en) * 2001-01-19 2002-12-17 Lec Tec Corporation Acne patch
WO2003088897A2 (en) * 2001-04-06 2003-10-30 Affinium Pharmaceuticals, Inc. Fab i inhibitors
US6503906B1 (en) 2002-02-21 2003-01-07 Ren-Jin Lee Method for optimizing ciprofloxacin treatment of anthrax-exposed patients according to the patient's characteristics
US7790709B2 (en) * 2002-12-06 2010-09-07 Affinium Pharmaceuticals, Inc. Heterocyclic compounds, methods of making them and their use in therapy
ATE409485T1 (de) 2003-03-17 2008-10-15 Affinium Pharm Inc Pharmazeutische zusammensetzungen inhibitoren von fab i und weitere antibiotika enthaltend

Also Published As

Publication number Publication date
EP1608377B1 (de) 2008-10-01
WO2004082586A2 (en) 2004-09-30
US20060142265A1 (en) 2006-06-29
DE602004016831D1 (de) 2008-11-13
CA2519429C (en) 2013-08-06
EP1608377A2 (de) 2005-12-28
CA2519429A1 (en) 2004-09-30
WO2004082586A3 (en) 2004-12-23
JP4880448B2 (ja) 2012-02-22
US20120010127A1 (en) 2012-01-12
US7879872B2 (en) 2011-02-01
JP2006523207A (ja) 2006-10-12

Similar Documents

Publication Publication Date Title
ATE409485T1 (de) Pharmazeutische zusammensetzungen inhibitoren von fab i und weitere antibiotika enthaltend
CO5600999A2 (es) Composiciones farmaceuticas que comprenden inhibidores de valsartan y endopeptidasa neutra
BRPI0518406A2 (pt) composiÇÕes tendo uma alta eficÁcia antiviral e antibacteriana
HN2001000244A (es) Inhibidores de espiropirimidin - 2, 4, 6 - triona metaloproteinasas.
UY26380A1 (es) Inhibidores de fab i
EA200300050A1 (ru) Гликопептидфосфонатные производные
SE0101387D0 (sv) Novel compounds
CY1110498T1 (el) Παραγωγα πυραζολης ως αναστολεις των κινασων τυροσινης υποδοχεα
TW200612950A (en) Quinazolinedione derivatives as PARP inhibitors
UY28138A1 (es) Intermedio de formulación aceptablemente no higroscópico que comprende un fármaco higroscópico
ATE369363T1 (de) Antibiotika mit doppelwirkung
UA91002C2 (ru) 7-фенилалкилзамещенные 2-хинолиноны и 2-хиноксалиноны как ингибиторы поле(адф-рибоза)полимеразы
NO20052787D0 (no) N-alkyl-4-metylenamino-3-hydroksy-2-pyridoner som antimikrobielle midler
SE0102315D0 (sv) Compounds
CY1108725T1 (el) Συνδυασμος ανταγωνιστου-nmda και αναστολεων ακετυλοχολινεστερασης δια την θεραπειαν της νοσου alzheimer
EA200600280A1 (ru) Композиции на основе производных липопептидных антибиотиков и способы их применения
CL2004000849A1 (es) Compuestos derivados de benzamidas-2-hidroxi-3-diaminoalcanos, utiles para el tratamiento o la prevencion de alzheimer, sindrome de down, hemorragia cerebral hereditaria, demencias degenerativas y otras.
ES2421948T3 (es) Compuestos y composiciones para suministrar agentes activos
PL375360A1 (en) Composition and antiviral activity of substituted azaindoleoxoacetic piperazine derivatives
CY1114133T1 (el) ΥΠΟΚΑΤΕΣΤΗΜΕΝΕΣ γ-ΦΑΙΝΥΛ-Δ-ΛΑΚΤΑΜΕΣ ΚΑΙ ΧΡΗΣΕΙΣ ΠΟΥ ΣΧΕΤΙΖΟΝΤΑΙ ΠΡΟΣ ΑΥΤΕΣ
ATE477256T1 (de) Thienylverbindungen
SE0101932D0 (sv) Pharmaceutical combinations
ECSP045397A (es) 6-ALQUILIDEN-PENEMS BICÍCLICOS COMO INHIBIDORES DE LAS b-LACTAMASAS
PA8586801A1 (es) Inhibidores de hiv-integrasa, composiciones farmaceuticas y metodos para su uso
UY27610A1 (es) Combinación de inhibidores de ptm o inhibidores de la secreción de apob con fibratos para la utilización como medicamentos

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties